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CANCER INCIDENCE IN FIRST AND SECOND DEGREE RELATIVES OF  
BRCA1 AND BRCA2 MUTATION CARRIERS 
Haley Streff, BS 
Advisory Professor: Jennifer Litton, M.D. 
Mutations in the BRCA1 or BRCA2 genes are associated with increased risks for breast, 
ovarian, and several other cancers.  The purpose of this study was to evaluate the incidence of 
cancers in first and second degree relatives of BRCA mutation carriers compared to the general 
population.  A total of 1086 pedigrees of BRCA mutation carriers were obtained from a 
prospectively maintained, internal review board approved study of persons referred for clinical 
genetic counseling at The University of Texas MD Anderson Cancer Center.  We identified 9032 
first and second degree relatives from 784 pedigrees which demonstrated a clear indication of 
parental origin of mutation.  Standardized incidence ratios (SIRs) were used to compare the 
observed incidence of 20 primary cancer sites to the expected incidence of each cancer based 
on calculated risk estimates according to a subject’s age.   
BRCA1 families had increased SIRs for breast and ovarian cancer (p<0.001) and 
decreased SIRs for kidney, lung, Non-Hodgkin’s lymphoma, prostate, and thyroid cancer 
(p<0.001).  BRCA2 families had increased SIRs for breast, ovarian, and pancreatic cancer 
(p<0.001) and decreased SIRs for kidney, lung, Non-Hodgkin’s lymphoma, thyroid, and uterine 
cancer (p<0.0025).  Analysis of only first degree relatives (n=4099) identified no decreased 
SIRs and agreed with the increased SIRs observed in the overall study population.  We 
confirmed previous reports of an association between breast, ovarian, and pancreatic caners 
with BRCA mutations. Additional research to quantify the relative risks of these cancers for 
BRCA mutation carriers can help tailor recommendations for risk reduction. 
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Introduction 
 Hereditary breast and ovarian cancer (HBOC) is caused by germline mutations in the BRCA1 
and BRCA2 genes which are autosomal dominant tumor suppressor genes that help ensure DNA 
damage in the cell is repaired prior to cell replication.  Since the discovery of the BRCA1 and BRCA2 
genes in 1994 and 1995, respectively, considerable research has been completed to analyze the 
cancer risks associated with these genes (Miki et al., 1994; Wooster et al., 1995).  Individuals with a 
BRCA1 or BRCA2 mutation have up to an 84% lifetime risk to develop breast cancer and up to a 
27% or 45% lifetime risk to develop ovarian cancer, respectively (Ford et al., 1998).  However, 
lifetime risks for cancers other than breast and ovarian cancer remain debated.   
The National Comprehensive Cancer Network (NCCN) has compiled well-established 
screening and surveillance guidelines for BRCA mutation carriers.  Recommendations to reduce 
risks for breast cancer in women include clinical breast exams beginning at age 25, annual breast 
MRI, or mammogram if MRI is unavailable, beginning at 25-29 years of age or based on family 
history, annual mammogram and breast MRI for women ages 30-75, and discussion of risk-
reducing mastectomies (NCCN, 2015).  Recommendations for women over age 75 should be 
considered on an individual basis (NCCN, 2015).  For ovarian cancer risk-reduction,  
recommendations should be given for a bilateral salpingo-oophorectomy between ages 35 and 40 
and upon completion of child bearing (NCCN, 2015).  The NCCN recommends male BRCA carriers 
complete breast self-exams and clinical breast exams every 12 months beginning at age 35 (NCCN, 
2015).  The guidelines also advise male BRCA2 carriers to begin, and BRCA1 carriers to consider, 
prostate cancer screening at age 40 (NCCN, 2015).  No specific guidelines exist for pancreatic cancer 
and melanoma which have an established association with BRCA mutations.   
Prior studies investigating cancer risks other than breast and ovarian in BRCA1 and BRCA2 
mutation carriers have reported inconsistent results and have been largely gathered from small, 
familial studies.  One of the larger studies to date completed by The Breast Cancer Linkage 
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Consortium (BCLC) in 1999 found BRCA2 mutation carriers have an increased risk for prostate and 
pancreatic cancer and a statistically significant increased risk for buccal cavity, pharynx, stomach, 
melanoma of the skin, gallbladder, and bile duct cancers (BCLC, 1999).  The increased risk for 
prostate and pancreatic cancer has been replicated by numerous other studies and the association 
between BRCA2 mutations and these cancers is accepted in clinical practice (BCLC, 1999; Iqbal et 
al., 2012; Johannsson et al., 1999; Lorenzo Bermejo & Hemminki, 2004; Mersch et al., 2014; Moran 
et al., 2012; van Asperen et al., 2005). 
Other studies describing increased risks for cancers other than breast and ovarian are 
conflicting.  Numerous reports debate whether an increased lifetime risk for any cancer beyond 
breast and ovarian cancer even exists across both sexes and genes (Moran et al., 2012; Thompson & 
Easton, 2002).  Multiple studies have agreed upon a significantly increased risk for pancreatic, 
prostate, and stomach cancers in all BRCA mutation carriers, but a consensus of the lifetime risks 
for these cancers continues to be debated and researched (BCLC, 1999; Brose, 2002; Johannsson et 
al., 1999; Noh et al., 2012).  An increased risk for colon cancer in BRCA mutation carriers has been 
described citing relative risks ranging from 0.82-4.8 in mutation carriers (Phelan et al., 2014; Sopik, 
Phelan, Cybulski, & Narod, 2014).  In 2014, Mersch, et al. completed one of the largest single 
institution studies of the incidence of non-breast and ovarian cancers in over 1,000 BRCA mutation 
carriers (Mersch et al., 2014).  An increased incidence of pancreatic and prostate cancer in BRCA2 
mutation carriers as well as increased occurrence of melanoma in BRCA1 carriers and cervical 
cancer in BRCA2 carriers was observed (Mersch et al., 2014).  Various other studies have reported 
an increased risk for melanoma of the skin, cervix, gallbladder, stomach, and uterine cancers; 
however, these have ranged from 1- to 4- fold increases, vary between BRCA1 and BRCA2 
mutations, and are inconsistently reported (BCLC, 1999; Johannsson et al., 1999; Moran et al., 2012; 
Thompson & Easton, 2002; van Asperen et al., 2005).   
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Current literature demonstrates inconsistencies with regards to risks for non-breast and 
ovarian cancers, and this study aims to further clarify and characterize the spectrum of cancer risks 
evident in families with a known BRCA1 or BRCA2 mutation.  It is essential to more clearly define 
the lifetime risks for non-breast and ovarian cancers associated with HBOC as they may inform the 
development of more comprehensive surveillance guidelines and improve the accuracy of risk 
assessment.  This study sought to determine whether the incidence of cancers was higher in 
families with a BRCA mutation than the general population.  We evaluated first degree relatives 
(FDR) and second degree relatives (SDR) of BRCA mutation carriers to describe the incidence of 
cancers in families with a BRCA mutation.   To our knowledge this is the largest study to be 
completed on a cohort of families with a BRCA mutation.  
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Methods 
This study was approved by the Institutional Review Board of the University of Texas MD 
Anderson Cancer Center (MDACC) (IRB #PA13-0650) and by the committee for the protection of 
human subjects of The University of Texas Health Science Center at Houston (IRB #HSC-GSBS-14-
0581).  Family histories of individuals who underwent genetic counseling at MDACC between 1997 
and 2014 with a confirmed deleterious BRCA1 or BRCA2 mutation were eligible for this analysis.  
Family histories included the sex, relation to proband, age, vital status, and cancer history for all 
FDR and SDR on the affected parental side of the proband.  Familial ethnicity and country of origin 
was provided by the proband when available.  For purposes of this study, if only an age decade was 
identified for a relative in the family history, the individual’s age was recorded as the middle age for 
that decade; for example, if 50s was reported as an individual’s age, the age was recorded as 55 
years old. 
A retrospective chart review of the pedigrees previously collected during genetic counseling 
visits with confirmed deleterious BRCA1 or BRCA2 mutations were completed for this study.  
Parental origin of the mutation was determined by the presence of a breast and/or ovarian cancer 
in a female first or second degree relative diagnosed before age 60 or a male first or second degree 
relative diagnosed with breast cancer at any age.  Pedigrees that did not meet these criteria or had 
breast and/or ovarian cancers in both paternal and maternal family histories were reviewed by 3 
authors (JP, JL, DN).  If a consensus of the parental origin of the mutation could not be determined, 
the pedigree was excluded from the study.  All FDR and SDR of the proband on the affected parental 
side were included in this analysis.  Relatives with no reported age or no reported age of cancer 
diagnosis were excluded in order to accurately account for an individual’s contribution of cancer 
risk to the study population which was calculated according to 5 year age intervals.   
The incidence of cancers found in the study population was compared to the general 
population incidence of cancers as reported by the United States Cancer Statistics: 1999-2011 
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Incidence and Mortality Web-based Report (USCS).  The defined reference time frame for age-
specific incidence rates in the USCS report was 2007-2011.  This report combines cancer registry 
data from the Centers for Disease Control and Prevention National Program of Cancer Registries 
and the National Cancer Institute’s Surveillance, Epidemiology and End Results Program.  There 
were 50 different cancers reported in the study population, but similar or related cancers were 
grouped together.  For example, gum, lip, oral, and throat cancer were grouped into oral cavity 
cancer and fallopian tube and primary peritoneal cancer were grouped with ovarian cancer.  This 
resulted in 42 cancer types in the study population.  The UCSC report included 20 of the 42 cancer 
types (USCS, 2014).  Cancers not included in the USCS report were excluded from the analysis.   
Observed number of cases for each cancer type was calculated based on the study 
population.  Expected number of cases was calculated by multiplying age, gender, ethnicity, and 
period specific person-years at risk by the corresponding general population cancer incidence 
rates.  Expected number of cases for each cancer type is the sum of expected numbers by age, 
gender, and ethnicity group.  Standardized incidence ratios (SIR) for each cancer type and its 
corresponding 95% confidence intervals (CIs) were calculated to compare the observed number of 
cases with the expected number of cases.  We also calculated the SIR stratifying by BRCA1 and 
BRCA2 mutation and by first and second degree relative status.  To adjust for multiple comparisons 
due to testing 20 cancer sites, a p value of <0.0025 (=0.05/20) was considered statistically 
significant. 
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Results 
We identified 1,086 individuals with a deleterious BRCA1 or BRCA2 mutation from 1997-
2014.  In 164 of the pedigrees, the parental origin of the mutation could not be determined and 
were excluded.  Sixty-one other pedigrees were eliminated from the study for numerous reasons: 
15 of the known mutation carriers did not have a pedigree available; 41 pedigrees lacked a 
comprehensive family history and did not include three generations; 2 pedigrees had the presence 
of another genetic conditions in the family (hereditary retinoblastoma and neurofibromatosis type 
1); and 3 pedigrees had both a BRCA1 and BRCA2 mutation in the family.  Seventy-seven of the 
reviewed pedigrees were determined to be duplicates due to another individual in the same family 
seeking site-specific testing.  In these cases, the proband of a given pedigree was considered to be 
the individual who presented to clinic first and only the most recent version of a family’s pedigree 
in the database was included in the analysis.  In total, 784 unique pedigrees were analyzed (Figure 
1).  
 
Figure 1: Positive BRCA1 and BRCA2 mutation carriers seen at MDACC 
*164 undetermined inheritance, 15 missing pedigrees, 2 other genetic conditions, 3 BRCA1 and 
BRCA2 mutations, 41 incomplete 
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In 784 pedigrees, 11,462 FDR and SDR were reported, but 2,089 individuals did not have an 
age reported and 439 individuals did not have an age of cancer diagnosis reported and were thus 
eliminated from the study.  A total of 9,032 relatives were included in this analysis.  Demographic 
characteristics including familial gene, sex, degree of relationship to the proband, and ethnicity are 
reported in Table 1.  The age of the study population followed a normal distribution curve with an 
average age of 45.2 years old and a range of 1-104 years old.  Majority of the population was living 
at the time the pedigree was collected (6,545, 72%). 
 
Table 1: Demographics of study population (n=9,032) 
 BRCA1 BRCA2 Total 
Total (n = 9,032) 5,237 (58%) 3,795 (42%) 9,032 (100%) 
Sex    
Male 2,401 (46%) 1,802 (47%) 4,203 (47%) 
Female 2,836 (54%) 1,993 (53%) 4,829 (53%) 
Degree of Relation  
FDR 2,430 (46%) 1,669 (44%) 4,099 (45%) 
SDR 2,807 (54%) 2,126 (56%) 4,933 (55%) 
Ethnicity  
White 3,679 (70%) 2,952 (78%) 6,631 (73%) 
Hispanic 912 (17%) 348 (9%) 1,260 (14%) 
Black 462 (9%) 306 (8%) 768 (9%) 
Asian/Pacific Islander 163 (3%) 134 (4%) 297 (3%) 
Am Indian/Native American 21 (1%) 55 (1%) 76 (1%) 
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Male breast cancer, which has a well-described association with BRCA mutations, was not 
analyzed as it was not included in the USCS report due to its low prevalence in the general 
population.  However, 24 cases of male breast cancer were identified in the study population; 12 
were of BRCA1 families and 12 were of BRCA2 families.  The average age of diagnosis of male breast 
cancer in BRCA1 families was 48 years (27-75 years) and 64 years (47-75 years) in BRCA2 families. 
We found multiple increased and decreased SIRs among BRCA1 and BRCA2 families 
described in Tables 2 and 3.  We observed an increased SIR in BRCA1 families for breast cancer (SIR 
3.37, 95% CI 3.09-3.67, p<0.0001) and ovarian cancer (SIR 14.31, 95% CI 12.28-16.58, p<0.0001).   
A trend of increasing incidence of pancreatic cancer (SIR 1.84, 95% CI 1.24-2.62, p=0.0030) was 
also observed in the BRCA1 population.  The average age of diagnosis of breast cancer was 46.1 
years old (24-95 years), ovarian cancer was 53.0 years old (25-88 years), and pancreatic cancer 
was 58.9 years old (24-88 years).  In BRCA2 families, breast (SIR 3.44, 95% CI 3.13-3.79, p<0.0001), 
ovarian (SIR 9.70, 95% CI 7.77-11.96, p<0.0001), and pancreatic (SIR 2.02, 95% CI 1.33-2.95, 
p=0.0013) cancer had an increased SIR.  Average age of diagnosis of breast cancer was 49.8 years 
(20-97), ovarian cancer was 57.1 years (23-80 years), and pancreatic cancer was 62.0 years (29-86 
years).  When stratifying the study population by sex, we found an increased SIR for pancreatic 
cancer (SIR 2.61, 95% CI 1.87-3.56, p<0.0001) when considering both BRCA1 and BRCA2 mutations 
in men.  Women, though, had an increased SIR for only breast (SIR 3.41, 95% CI 3.19-3.63, 
p<0.0001) and ovarian (SIR 12.37, 95% CI 10.92-13.96, p<0.0001) cancer. 
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Table 2: Cancer sites with significantly increased SIRs (p <0.0025) 
Cancer Site Gene Observed Expected SIR 95% CI P value 
Breast BRCA1 534 158.4 3.37 3.09-3.67 <0.0001 
Breast BRCA2 435 126.1 3.45 3.13-3.79  <0.0001 
Ovarian BRCA1 177 12.4 14.31 12.28-16.58 <0.0001 
Ovarian BRCA2 87 9.0 9.70 7.77-11.96 <0.0001 
Pancreas* BRCA1 30 16.3 1.84 1.24-2.62 0.0030 
Pancreas BRCA2 27 13.3 2.02 1.33-2.95 0.0013 
*Trending (p < 0.007) 
Several cancers were also observed to have a decreased SIR (p<0.0025); in BRCA1 families 
there was a decreased SIR for kidney, lung, Non-Hodgkin’s lymphoma, prostate, and thyroid cancer.  
In BRCA2 families a decreased SIR for kidney, lung, Non-Hodgkin’s lymphoma, thyroid, and uterine 
cancer was observed.  Men in the BRCA1 population had a decreased SIR for kidney, lung, Non-
Hodgkin’s lymphoma, oral cavity, and prostate cancer and men in BRCA2 families had a decreased 
SIR for Non-Hodgkin’s lymphoma.  Women of BRCA1 families had a decreased SIR for lung, Non-
Hodgkin’s lymphoma, and thyroid cancer while women of BRCA2 families had a decreased SIR for 
lung, melanoma, thyroid, and uterine cancer. 
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Table 3: Cancer sites with significantly decreased SIRs (p <0.0025) 
Cancer Site Gene Observed Expected SIR 95% CI P value 
Kidney BRCA1 5 23.9 0.21 0.07-0.49 <0.0001 
Kidney BRCA2 6 19.2 0.31 0.11-0.68 0.0009 
Lung BRCA1 33 83.8 0.40 0.27-0.55 <0.0001 
Lung BRCA2 30 70.8 0.42 0.29-0.61 <0.0001 
Non-Hodgkin’s BRCA1 8 27.8 0.29 0.12-0.57 <0.0001 
Non-Hodgkin’s BRCA2 4 22.4 0.18 0.08-0.46 <0.0001 
Prostate BRCA1 53 91.7 0.58 0.43-0.76 <0.0001 
Thyroid BRCA1 8 24.9 0.32 0.14-0.63 0.0002 
Thyroid BRCA2 7 19.3 0.36 0.15-0.75 0.0025 
Uterine BRCA2 4 16.8 0.24 0.06-0.61 0.0004 
 
 When considering only FDR, no decreased SIRs were identified.  We observed FDR of BRCA1 
families had an increased SIR for breast (SIR 4.37, 95% CI 3.86-4.93, p<0.0001), ovarian (SIR 21.9, 
95% CI 17.59-26.95, p<0.0001), and pancreatic (SIR 3.53, 95% CI 1.88-6.04, p<0.0003) cancer.  
Similarly, FDR of BRCA2 families had an increased SIR for breast (SIR 4.57, 95% CI 3.98-5.22, 
p<0.0001), ovarian (SIR 12.61, 95% CI 9.98-19.53, p<0.0001), and pancreatic (SIR 3.77, 95% CI 
1.95-6.58, p<0.0001) cancer which agrees with the previously reported data when SDR are 
included as well as established cancer risks in HBOC.  Additionally, a trend for an increased 
incidence of prostate cancer was observed in BRCA2 families (SIR 1.63, 95% CI 1.15-2.23, 
p=0.0067). 
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Discussion 
 This study aimed to further define the cancers associated with BRCA mutations through 
analysis of the incidence of cancers in first and second degree relatives of known BRCA1 and BRCA2 
mutation carriers.  The results confirm the recognized increased incidence of breast and ovarian 
cancer in females with a BRCA mutation.  Additionally, this study confirms an association between 
BRCA mutations and pancreatic cancer based on the increased incidence of pancreatic cancer in 
BRCA2 families and the trending increased incidence of pancreatic cancer in BRCA1 families.  The 
increased SIRs for breast and ovarian cancer in both BRCA1 and BRCA2 families and for pancreatic 
cancer in BRCA2 families are consistent with results from Mersch, et al. who examined the incidence 
of non-breast and ovarian cancers in the BRCA mutation-positive probands of this current study 
(Mersch et al., 2014).  The increased incidence of prostate cancer in BRCA2 mutation carriers found 
by Mersch, et al. is also supported by this study when analyzing only FDR in the study population. 
Several studies have investigated the cancer risks for HBOC in cohorts of individuals 
without confirmed BRCA1 or BRCA2 mutations similar to this study population.  In studies 
regarding BRCA1, increased risks for pancreatic, prostate, and uterine body/cervical cancer have 
been reported in cohorts of individuals with unknown BRCA mutation carrier status (Thompson & 
Easton, 2002).  Our results are consistent with the increased incidence of pancreatic cancer, but 
failed to find an association with prostate cancer or uterine body/cervical cancer.  In BRCA2 
research, increased risks for breast, ovarian, pancreatic, prostate, bone, and pharynx cancer, and 
uveal melanoma have been reported in populations which include unconfirmed BRCA mutation 
carriers (Moran et al., 2012; van Asperen et al., 2005).  Melanoma, breast, ovarian, pancreatic, and 
prostate cancers are all mentioned in the NCCN guidelines for HBOC (NCCN, 2015).  Excluding 
melanoma, these findings were replicated when considering just FDR.  The increased risks for bone 
and pharynx cancer identified by Van Asperan, et al. have not been replicated to our knowledge 
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(van Asperen et al., 2005).  This study did not analyze bone cancer and found no significant 
incidence of pharynx cancer. 
No previously unreported associations of specific cancers with BRCA mutations were 
identified in this study and relatively few cancers had a significantly increased SIR when compared 
to other reports.  However, many of these studies were based on analysis of confirmed BRCA1 and 
BRCA2 mutation carriers (Brose, 2002; Iqbal et al., 2012; Johannsson et al., 1999; Mersch et al., 
2014; Noh et al., 2012; Phelan et al., 2014).  Because only half of our study population is assumed to 
have a BRCA mutation, we expected that cancers associated with BRCA mutations would not have as 
high an incidence as they would in a population comprised solely of known mutation carriers.  Still, 
the outcomes of the present study may be more helpful in the development and review of screening 
protocols for HBOC because individuals seeking surveillance may be at risk for a known familial 
mutation but be untested. 
Focusing on only FDR in the study population is beneficial to account for patient-reported 
family histories and should provide the most precise and accurate interpretation of results.  This 
study relies on the accuracy of reported family histories which has been shown to be reduced in 
distant relatives.  Studies examining the accuracy of patient-reported family histories indicate that 
the site of a cancer diagnosis in FDR and SDR is correctly reported in 78-95% and 53-67% of cases, 
respectively (Love, Evans, & Josten, 1985; Schneider et al., 2004; Ziogas & Anton-Culver, 2003).  
When considering only FDR, the incidences of cancers in the study population align almost 
completely with the previously established cancer associations for BRCA mutations.  FDR of BRCA1 
mutation carriers demonstrated an increased SIR for breast, ovarian, and pancreatic cancer and the 
FDR of BRCA2 carriers likewise revealed an increased SIR for breast, ovarian, and pancreatic cancer 
in addition to a trending increased SIR for prostate cancer.  These cancer associations are all 
reported by the NCCN and information regarding risk reduction and surveillance recommendations 
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for these cancers are addressed in the guidelines for HBOC (NCCN, 2015).  Furthermore, no 
decreased SIRs were observed in the population of only FDR. 
Studies suggest that underreporting of cancer is more common than over reporting of 
cancers in family histories (Love et al., 1985; Ozanne et al., 2012; Quillin et al., 2006; Ziogas & 
Anton-Culver, 2003).  The overall accuracy of patient-reported family history is dependent on age, 
education, sex, degree of relation, and socioeconomic status of the patient or historian (Ozanne et 
al., 2012; Quillin et al., 2006; Schneider et al., 2004).  Family structure and dynamics, social stigma, 
and communication barriers may likewise contribute to an underreporting bias in a family history.  
Also, for individuals of older generations, cancers may have gone undiagnosed as cancer detection 
and prevention measures improve with time and new technology (Singh, Sethi, Raber, & Petersen, 
2007).  Moreover, pedigrees in which a complete family history was not reported (i.e. no paternal 
history known) were eliminated from the study if the parental origin of the mutation was not 
confirmed or could not be inferred.  The influence of these factors may be reduced in the FDR 
population and may also provide explanations for the number of decreased SIRs observed in the 
overall study population when SDR were included in the analysis. 
The average age of diagnosis of breast and ovarian cancer in individuals with BRCA 
mutations is expected to be lower than an individual without a mutation in the general population 
(Litton et al., 2012; Panchal et al., 2010).  The average age of diagnosis for breast and ovarian 
cancer in the general population is 61 years old and 63 years old, respectively (Howlader N, 2014).  
The average age of breast cancer diagnosis in the study population was 47.8 years old and 54.4 
years old for ovarian cancer.  This data generally agrees with recommendations of the NCCN to 
begin breast imaging in mutation carriers at 25 years of age as only 6 of the 968 (0.62%) reported 
cases of breast cancer were diagnosed prior to age 25.  The NCCN guidelines do account for the use 
of family history information for making individualized screening recommendations (NCCN, 2015).  
Therefore some of these individuals may have begun screening before age 25 based on family 
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history.  The NCCN also recommends prophylactic bilateral salpingo-oophorectomy at 35-40 years 
and upon completion of child-bearing (NCCN, 2015).  Fourteen of the 166 (8.4%) cases of ovarian 
cancer were diagnosed prior to age 35 and 28 (16.9%) cases were diagnosed prior to age 40.  Again, 
the NCCN guidelines advise that clinicians consider personal and family history information when 
making recommendations.  
While this study allowed for analysis of a large number of relatives, the data is limited to 
one time point, as this was a retrospective data collection, so instances of cancer diagnosed after the 
date the pedigree was last updated are not included.  For example, when interpreting the current 
results for prostate cancer, previous literature and the NCCN report an increased risk for prostate 
cancer in male BRCA2 mutation carriers and a likely increased risk in BRCA1 mutation carriers.  
Therefore we expect an increased SIR for prostate cancer in the study population.  However, the 
results of this study found a decreased SIR for BRCA1 mutation families.  The average age of men in 
the BRCA1 population was 43.8 years old (1-104 years) and the average age of prostate cancer 
diagnosis is 66 years old in the general population with BRCA carriers under age 65 having an 
increased relative risk for prostate cancer of 1.44-3.75 (Howlader N, 2014; Leongamornlert et al., 
2012; Thompson & Easton, 2002).  Therefore, more of the men in the BRCA1 study cohort may 
develop prostate cancer in their lifetime which would increase the incidence in the study 
population and alter results.   
Given that family history of cancer can evolve over time, the statistical analysis did account 
for each individual’s contribution to the cancer risk of the study population based on ethnicity, sex, 
and age in 5-year intervals.  Similarly, the pedigrees in the analysis were prospectively updated if 
the proband proactively provided new family history information or clarifications.  However, this 
additional information may be more likely to only include clarifications regarding diagnoses of 
previously defined BRCA-associated cancers and not other cancer diagnoses which may induce a 
collection bias.  A prospective study may help reduce this bias and could possibly obtain more 
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accurate current ages, ages of cancer diagnoses, environmental exposures, surgical histories, and 
health histories, but knowledge of family history information may remain vague or ambiguous 
regardless of study design. 
This study has limitations that should be considered when interpreting data.  First, multiple 
cancers included in this analysis have known environmental risk factors and lifestyle choices like a 
history of tobacco use, obesity, sun exposure, or completion of surgeries or procedures, that 
increase or decrease an individual’s risk for cancer ("American Cancer Society: What Causes 
Cancer?," 2015).  Environmental exposures and/or surgical decisions in family members are not 
consistently reported during a family history intake; therefore we are unable to comment on their 
influence on the results.  Also, because the majority of pedigrees were obtained in a clinical setting, 
a collection bias in the population may be present.  A genetic counselor may ask more detailed 
questions to clarify reports of cancers only related to the syndrome of interest (i.e. breast, ovarian, 
pancreatic cancer in HBOC) and not explore cancers without an association with a hereditary 
cancer syndrome as thoroughly.  If a specific age or cancer diagnosis was not clarified and reported 
on the pedigree, then that individual would have been excluded from this study consequently 
decreasing the incidence of that cancer in the study population.  Therefore, cancers without a 
previous association to HBOC or a hereditary cancer syndrome may be underreported in the study 
population.  Finally, the data cannot be generalized to individuals of all ethnicities given that the 
study population is predominantly Caucasian.   
Moving forward, studies may wish to focus on non-Caucasian ethnicity specific cancer risks 
in HBOC because to our knowledge, most other studies on BRCA mutation carriers are based on a 
majority Caucasian population.  Further investigation to obtain more specific lifetime relative risks 
for the cancers associated with HBOC should also be completed.  Cohorts of known BRCA mutation 
carriers with their at-risk family members can be used as an unbiased population to better 
determine these risks and define age-specific incidence rates for more appropriate risk 
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assessments for BRCA families.  Additionally, more work to enhance screening and surveillance 
guidelines for mutation carriers is indicated as pancreatic cancer currently does not have well-
established surveillance methods and recommendations for prostate cancer screenings are vague.  
Screening guidelines from the NCCN acknowledge all of the cancer associations of BRCA mutations 
identified in this study, but risk reduction data and strategies may still be evolving. 
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Conclusion 
The utilization of a cohort of individuals with an unknown BRCA mutation status from 
families with a known BRCA mutation allowed for a large sample size that demonstrated a 
comprehensive analysis of cancer incidence in HBOC.  This study supports previous reports of an 
association between BRCA1 and BRCA2 mutations and breast cancer, ovarian cancer, and pancreatic 
cancer.  Analysis of only FDR similarly confirmed an association between BRCA1 mutations with 
breast, ovarian, and pancreatic cancers and BRCA2 mutations with breast, ovarian, pancreatic, and 
prostate cancers.   This study did not find any cancers to be associated with BRCA mutations that 
have not been addressed in the NCCN guidelines or have not had a previously well-established and 
accepted association with HBOC.  Results of this study indicate the spectrum of cancers associated 
with BRCA1 and BRCA2 mutations seems to be fairly well-defined at this time. 
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Appendix 1: SIRs for all cancer sites for BRCA1 and BRCA2 
Cancer Site Gene Observed  Expected  SIR 95% CI  P value 
Bladder BRCA1 12 25.3 0.47 0.25-0.83 0.0052 
Bladder BRCA2 13 21.4 0.61 0.32-1.04 0.0744 
Brain BRCA1 9 12.3 0.73 0.33-1.39 0.4278 
Brain BRCA2 6 9.8 0.61 0.23-1.34 0.2923 
Breast BRCA1 534 158.4 3.37 3.09-3.67 <0.0001 
Breast BRCA2 435 126.1 3.45 3.13-3.79 <0.0001 
Colorectal BRCA1 43 59.6 0.72 0.52-0.97 0.0302 
Colorectal BRCA2 29 48.4 0.60 0.40-0.86 0.0036 
Cervical BRCA1 6 8.2 0.73 0.27-1.59 0.5714 
Cervical BRCA2 6 6.0 0.99 0.36-2.16 1.0000 
Esophageal BRCA1 11 6.3 1.74 0.87-3.11 0.1155 
Esophageal BRCA2 10 5.3 1.89 0.91-3.48 0.0866 
Hodgkin’s BRCA1 3 5.9 0.51 0.11-1.45 0.3269 
Hodgkin’s BRCA2 3 4.5 0.66 0.14-1.94 0.6779 
Kidney BRCA1 5 23.9 0.21 0.07-0.49 <0.0001 
Kidney BRCA2 6 19.2 0.31 0.11-0.68 0.0009 
Leukemia BRCA1 10 21.2 0.47 0.23-0.87 0.0111 
Leukemia BRCA2 11 16.7 0.66 0.33-1.18 0.1934 
Lung BRCA1 33 83.8 0.39 0.27-0.55 <0.0001 
Lung BRCA2 30 70.8 0.42 0.29-0.61 <0.0001 
Melanoma BRCA1 16 27.5 0.58 0.33-0.95 0.0260 
Melanoma BRCA2 10 23.3 0.42 0.21-0.79 0.0033 
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Myeloma BRCA1 2 8.1 0.24 0.03-0.89 0.0255 
Myeloma BRCA2 2 6.5 0.31 0.04-1.12 0.0885 
Non-Hodgkin’s BRCA1 8 27.8 0.29 0.12-0.57 <0.0001 
Non-Hodgkin’s BRCA2 4 22.4 0.18 0.05-0.46 <0.0001 
Oral Cavity BRCA1 8 16.0 0.50 0.22-0.99 0.0450 
Oral Cavity BRCA2 5 13.2 0.38 0.12-0.88 0.0186 
Ovarian BRCA1 177 12.4 14.31 12.28-16.58 <0.0001 
Ovarian BRCA2 87 9.0 9.70 7.77-11.96 <0.0001 
Pancreas BRCA1 30 16.3 1.84 1.24-2.63 0.0030 
Pancreas BRCA2 27 13.3 2.02 1.33-2.95 0.0013 
Prostate BRCA1 53 91.7 0.58 0.43-0.76 <0.0001 
Prostate BRCA2 79 79.2 1.00 0.79-1.24 1.0000 
Stomach BRCA1 15 9.9 1.51 0.85-2.49 0.1589 
Stomach BRCA2 11 7.6 1.45 0.72-2.59 0.2934 
Thyroid BRCA1 8 24.9 0.32 0.14-0.63 0.0002 
Thyroid BRCA2 7 19.3 0.36 0.15-0.75 0.0025 
Uterine BRCA1 12 21.1 0.57 0.29-0.99 0.0467 
Uterine BRCA2 4 16.8 0.24 0.07-0.61 0.0004 
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